Deciduous Therapeutics
San Francisco, US · Founded 2018 · Delaware corporation · 8 known investors
Deciduous Therapeutics develops small molecule and immunomodulatory therapies targeting senescent cells to treat age-related diseases including Type 1 diabetes, autoimmunity, and metabolic disorders. The company serves patients with conditions driven by cellular aging and senescence.
Founders & leadership
Deciduous Therapeutics was founded in 2018 by Robin Mansukhani and Anil Bhushan.
Board
DM
Investors · 8
Reported raises · per SEC filings
Form D private placements$5.8M disclosed across 1 round · 2019
▶$5.8MraisedJul 2019 · 10 investors · BiotechnologyRule 506(b)
▶$5.8MraisedJul 2019 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robin MansukhaniExecutive Officer, Director
- Dylan MorrisDirector
- Anil BhushanDirector
- Offering amount
- $6.5M
- Amount sold
- $5.8M
- Minimum investment
- $10K
- First sale
- Jun 2019
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 6
by search overlapDialectic Therapeutics7 shared keywordsDialectic Therapeutics is a clinical-stage biotechnology company developing anti-cancer drugs using its Antiapoptotic Protein Targeted Degradation (APTaD) platform, which induces cancer cells to degrade proteins such as BCL-XL. Its lead candidate, DT2216, is in Phase 1/2 trials for fibrolamellar carcinoma and platinum-resistant ovarian cancer.
Dewpoint Therapeutics5 shared keywordsDewpoint Therapeutics develops condensate-modulating drugs by using an integrated platform that maps, measures, and modulates biomolecular condensates to identify druggable targets and disease mechanisms. Its discovery engine combines biology, chemistry, proprietary datasets, and AI to pursue therapies for complex diseases, including previously undruggable targets.
Edgewise Therapeutics4 shared keywordsEdgewise Therapeutics develops novel therapeutics for serious cardiovascular muscle diseases, including hypertrophic cardiomyopathy (HCM) and heart failure. The company focuses on drug development targeting cardiac muscle for patients with life-limiting cardiovascular conditions.
Celldex Therapeutics, Inc.4 shared keywordsCelldex is a biotechnology company developing therapeutics across therapeutic areas including immunology and inflammation. The page shown is a board director biography rather than a company overview.
Kite Pharma3 shared keywordsKite Pharma develops CAR T-cell therapies for cancer patients, engineering the immune system's cells to target and attack cancer. Each therapy is individualized per patient through a multi-step manufacturing process.
Preqin3 shared keywordsPreqin provides private markets data, analytics, and benchmarking across private equity, venture capital, hedge funds, real estate, private credit, infrastructure, secondaries, and natural resources. Its products serve fund managers, investors, consultants, banks, and other financial professionals for fundraising, manager selection, due diligence, and performance analysis.
Companies competing with Deciduous Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Deciduous Therapeutics do?
- Deciduous Therapeutics develops small molecule and immunomodulatory therapies targeting senescent cells to treat age-related diseases including Type 1 diabetes, autoimmunity, and metabolic disorders. The company serves patients with conditions driven by cellular aging and senescence.
- Who founded Deciduous Therapeutics?
- Deciduous Therapeutics was founded by Robin Mansukhani, Anil Bhushan in 2018.
- Who are Deciduous Therapeutics's investors?
- Deciduous Therapeutics's investors include age1, Bold Capital Partners, Cornucopian Capital Management, CRV (Charles River Ventures), Owl Capital, quadraScope Venture Fund, Axial VC, Mana Ventures.
- How much funding has Deciduous Therapeutics raised?
- Deciduous Therapeutics has disclosed $5.8M raised across 1 round.
- Where is Deciduous Therapeutics headquartered?
- Deciduous Therapeutics is headquartered in San Francisco, US.